Aptevo Seeks Shareholder Nod for 145,000-Share Equity Plan to Preserve Cash
APVO is trading near its 52-week low of $3.68 (12% above the low).
Summary
Aptevo Therapeutics asks shareholders to approve a 145,000-share increase to its equity incentive plan, representing potential dilution of ~9.6%, to conserve cash and retain employees amid a going concern warning.
Key Events · Corporate Governance and Compliance · APVO
-
Equity Plan Expansion Requested
Proposal 4 seeks approval for 145,000 additional shares under the Fourth Amended and Restated 2018 Stock Incentive Plan, increasing the total reserve to ~152,360 shares. Based on 1,517,945 shares outstanding, this represents potential dilution of approximately 9.6% if all shares are granted.
-
Cash Conservation Driver
The company states that without the additional shares, it may be forced to increase cash compensation, reducing resources available for business needs. Only 7,360 shares remain available for grants as of July 23, 2026.
-
Financial Distress Context
The proxy follows a 10-Q filed May 13, 2026, which reiterated a going concern warning and reported a net loss of $25.9M for 2025. The company had $14.5M in cash as of March 31, 2026, and a $60M equity line of credit.
-
Annual Meeting and Governance
The annual meeting is scheduled for August 21, 2026. Proposals include the election of two directors, ratification of Baker Tilly as auditor, an advisory say-on-pay vote, and the stock plan approval.
Analysis · APVO · Life Sciences
Aptevo's proxy filing asks shareholders to authorize 145,000 new shares for its stock incentive plan — a roughly 9.6% potential dilution against the current 1.5 million shares outstanding. With only 7,360 shares left for grants, the company warns that without approval it may be forced to increase cash compensation, straining its already tight resources. This request arrives against a backdrop of a going concern warning, a $25.9M net loss in 2025, and a stock price near $4. The plan is designed to retain key talent as the company advances its clinical pipeline, but the dilution adds to the overhang from existing warrants and institutional holdings. The annual meeting is set for August 21, 2026.
At the time of this filing, APVO was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $3.68 to $52.73. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.